Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8225348 | 0.93 | KMT2A (0.58) | KMT2AMEN1KDM4ETP53MAPK1 | |
| SCHEMBL1600111 | 0.86 | KMT2A (0.65) | KMT2AMEN1KDM4ETP53MAPK1 | |
| SCHEMBL16485461 | 0.83 | MEN1 (0.51) | KMT2AMEN1KDM4ETP53MAPK1 | |
| SCHEMBL18182316 | 0.80 | MAPK1 (0.72) | KMT2AMEN1KDM4ETP53MAPK1 | |
| SCHEMBL16884151 | 0.80 | GAA (0.63) | KMT2AMEN1KDM4ETP53MAPK1 | |
| SCHEMBL13886164 | 0.79 | CRHBP (0.73) | KMT2AMEN1KDM4ETP53MAPK1 | |
| SCHEMBL5755240 | 0.79 | HTT (0.67) | KMT2AMEN1TP53MAPK1ALDH1A1 | |
| SCHEMBL28191613 | 0.79 | GAA (0.66) | KMT2AMEN1KDM4ETP53MAPK1 | |
| SCHEMBL2601955 | 0.78 | POLB (0.61) | KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL26113758 | 0.77 | KMT2A (0.56) | KMT2AMEN1KDM4ETP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-8895554-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease | PROTEOTECH INC (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140038980-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTAMED, INC. | 2014-02-06 | — | — | US | disclosed |
| US-8586585-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease | PROTEOTECH, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130245128-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTAMED, INC. | 2013-09-19 | — | — | US | disclosed |
| US-20120225890-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND PARKINSON'S DISEASE | PROTAMED, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8163957-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease | PROTEOTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110172239-A1 | Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease | PROTAMED, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225890-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND PARKINSON'S DISEASE | IAPP, SNCA, APP | KMT2A 3543/4885MEN1 2549/4885KDM4E 3701/4885 |
| US-20140038980-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | IAPP, SNCA, APP | KMT2A 3808/4885MEN1 2588/4885KDM4E 3994/4885 |
| US-20130245128-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | IAPP, SNCA, APP | KMT2A 4448/4885MEN1 3057/4885KDM4E 4065/4885 |
| US-20110172239-A1 | Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease | IAPP, SNCA, APP | KMT2A 3543/4885MEN1 2549/4885KDM4E 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.